Source 1primary paper2025MED
Toolkit/macrocyclic peptide targeted protein degraders
macrocyclic peptide targeted protein degraders
Also known as: macrocyclic peptides as targeted protein degraders
Taxonomy: Mechanism Branch / Architecture. Workflows sit above the mechanism and technique branches rather than replacing them.
Summary
Here, we consider the potential of macrocyclic peptides to overcome this limitation.
Usefulness & Problems
Why this is useful
Macrocyclic peptides are proposed here as a degrader modality that could direct targeted protein degradation through the ubiquitin-proteasome system. The abstract frames them as a new class of targeted protein degraders rather than a single validated construct.; broadening targeted protein degrader access beyond targets tractable by traditional small molecules; potentially expanding the set of E3 ligases that can be harnessed for degradation
Source:
Macrocyclic peptides are proposed here as a degrader modality that could direct targeted protein degradation through the ubiquitin-proteasome system. The abstract frames them as a new class of targeted protein degraders rather than a single validated construct.
Source:
broadening targeted protein degrader access beyond targets tractable by traditional small molecules
Source:
potentially expanding the set of E3 ligases that can be harnessed for degradation
Problem solved
The paper proposes macrocyclic peptides as a way to address the limited proteome coverage of current degrader designs, which are said to apply to roughly 15% of the human proteome.; limited target scope of existing targeted degrader design
Source:
The paper proposes macrocyclic peptides as a way to address the limited proteome coverage of current degrader designs, which are said to apply to roughly 15% of the human proteome.
Source:
limited target scope of existing targeted degrader design
Problem links
limited target scope of existing targeted degrader design
LiteratureThe paper proposes macrocyclic peptides as a way to address the limited proteome coverage of current degrader designs, which are said to apply to roughly 15% of the human proteome.
Source:
The paper proposes macrocyclic peptides as a way to address the limited proteome coverage of current degrader designs, which are said to apply to roughly 15% of the human proteome.
Taxonomy & Function
Primary hierarchy
Mechanism Branch
Architecture: A reusable architecture pattern for arranging parts into an engineered system.
Target processes
degradationImplementation Constraints
cofactor dependency: cofactor requirement unknownencoding mode: genetically encodedimplementation constraint: context specific validationoperating role: regulator
The modality depends on the ubiquitin-proteasome system and on forming ternary complexes with target proteins and E3 ligases. The abstract also links their design logic to E3 ligase-recruiting peptide degrons.; requires leveraging the ubiquitin-proteasome system for catalytic degradation
The abstract does not show that macrocyclic peptides eliminate broader therapeutic development challenges, and it explicitly notes that targeted degraders are likely to face many of the same challenges as traditional small molecules.; therapeutic development may face many of the same challenges as traditional small molecules
Validation
Cell-freeBacteriaMammalianMouseHumanTherapeuticIndep. Replication
Supporting Sources
Ranked Claims
Macrocyclic peptides are well-suited for targeted degradation because they can induce ternary protein complexes involving relatively flat surfaces and share structural commonality with E3 ligase-recruiting peptide degrons.
Macrocyclic peptides have the potential to overcome the target-scope limitation of existing targeted degrader design.
Macrocyclic peptides provide the opportunity to broaden both the number of targets accessible to degrader activity and the number of E3 ligases that can be harnessed to mediate that activity.
Approval Evidence
1 source3 linked approval claimsfirst-pass slug macrocyclic-peptide-targeted-protein-degraders
Here, we consider the potential of macrocyclic peptides to overcome this limitation.
Source:
mechanistic rationalesupports
Macrocyclic peptides are well-suited for targeted degradation because they can induce ternary protein complexes involving relatively flat surfaces and share structural commonality with E3 ligase-recruiting peptide degrons.
Source:
proposed advantagesupports
Macrocyclic peptides have the potential to overcome the target-scope limitation of existing targeted degrader design.
Source:
scope expansionsupports
Macrocyclic peptides provide the opportunity to broaden both the number of targets accessible to degrader activity and the number of E3 ligases that can be harnessed to mediate that activity.
Source:
Comparisons
Source-stated alternatives
The abstract contrasts this proposed modality with existing targeted degraders such as PROTACs and molecular glues, and with traditional small-molecule-targeting approaches.
Source:
The abstract contrasts this proposed modality with existing targeted degraders such as PROTACs and molecular glues, and with traditional small-molecule-targeting approaches.
Source-backed strengths
can induce ternary protein complexes involving relatively flat surfaces; share structural commonality with E3 ligase-recruiting peptide degrons
Source:
can induce ternary protein complexes involving relatively flat surfaces
Source:
share structural commonality with E3 ligase-recruiting peptide degrons
Compared with molecular glues
The abstract contrasts this proposed modality with existing targeted degraders such as PROTACs and molecular glues, and with traditional small-molecule-targeting approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: can induce ternary protein complexes involving relatively flat surfaces; share structural commonality with E3 ligase-recruiting peptide degrons.
Relative tradeoffs: therapeutic development may face many of the same challenges as traditional small molecules.
Source:
The abstract contrasts this proposed modality with existing targeted degraders such as PROTACs and molecular glues, and with traditional small-molecule-targeting approaches.
Compared with proteolysis targeting chimera
The abstract contrasts this proposed modality with existing targeted degraders such as PROTACs and molecular glues, and with traditional small-molecule-targeting approaches.
Shared frame: source-stated alternative in extracted literature
Strengths here: can induce ternary protein complexes involving relatively flat surfaces; share structural commonality with E3 ligase-recruiting peptide degrons.
Relative tradeoffs: therapeutic development may face many of the same challenges as traditional small molecules.
Source:
The abstract contrasts this proposed modality with existing targeted degraders such as PROTACs and molecular glues, and with traditional small-molecule-targeting approaches.
Ranked Citations
- 1.